Pharma Equity Group A/S announced a private placement to issue 3.25% convertible term loan for the gross proceeds of DKK 7,100,000 on February 7, 2024. The loan is granted as a subordinated loan and is thus subordinated to the company's other creditors, except any other equivalent subordinated loan. The loan bears interest at 3.25% per quarter and remains without instalments until the end of the Exercise Period, after which the Company must repay the loan including interest within 60 days, however, the Company may extend the loan period by 12 months. The company can choose to pay the loan including interest in shares. Upon conversion of the loans into new shares, the new shares will be without pre-emptive rights for the company's existing shareholders and with the same rights as the company's existing shares. The new shares will therefore be admitted to trading on Nasdaq Copenhagen. The conversion will take place at par, so that an amount of DKK 1.00 will be converted into one new share of DKK 1.00 each in the Company. The maximum increase in share capital as a result of conversion of the convertible loans is DKK 10,427,806. The remaining terms of the convertible loan will be laid down in a convertible loan agreement and the Board of Directors' decision on the issuance of the convertible loan will be included in its entirety in the company's articles of association. The maximum increase in the share capital as a result of the conversion thereof is DKK 9,693,623. The subscription is composed of major shareholders, including a new shareholder in the Company, in Pharma Equity Group with DKK 5,500,000.

On the same date, the company announced that it has issued DKK 6,600,000 in its first tranche. DKK 1,600,000 has been subscribed by the company's chairman of the board Christian Vinding Thomsen, by board member Lars Gundorph and by the company's managing director, Thomas Kaas Selsø. Subscriptions have also been made for approx. DKK 900,000 from the deputy chairman of the board of the subsidiary Reponex Pharmaceuticals A/S, Troels Peter Troelsen. With reference to company announcement no. 01 of January 22, 2024, the total issuance of convertible loans thus amounts to DKK 16,014,795, and the maximum capital increase due to conversion of the convertible loans is DKK 23,055,497. With reference to the company announcement no. 03 of 25 January 25, 2024, as of the date of this company announcement, a total of DKK 15,514,795 has been subscribed and paid to the company, after which the total capital increase due to conversion of already subscribed convertible loans is DKK 22,321,314.The Board of Directors will inform the market of the outcome of the subscription of the remaining part of the convertible debt.